Washington: Days after US-based biotechnology Moderna’s vaccine showed 94.5 per cent efficacy in fight against COVID-19 infection, the Company’s Chief Executive Officer said that they will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered. Also Read - Centre Asks States, UTs to Take Steps to Reopen Medical Colleges From or Before Dec 1

“Our vaccine therefore costs about the same as a flu shot, which is between $10 and $50,” Reuters quoted Chief Executive Stephane Bancel as saying. Also Read - Public Dealing by Indian Embassy in Berlin To Remain Suspended Till Further Notice

Speaking on the likely deal with the European Commission for the supply of millions of doses for a price below $25 per dose, the CEO said, “Nothing is signed yet, but we’re close to a deal with the EU Commission. We want to deliver to Europe and are in constructive talks.” Also Read - COVID-19: European Union Says First Virus Vaccinations Possible By Christmas

Based on these interim safety and efficacy data, Moderna intends to submit for an Emergency Use Authorisation (EUA) with the US Food and Drug Administration (USFDA) in the coming weeks and anticipates having the EUA informed by the final safety and efficacy data.

Moderna also plans to submit applications for authorisations to global regulatory agencies.

By the end of 2020, the company expects to have approximately 20 million doses of mRNA-1273 ready to ship in the US. The Company remains on track to manufacture 500 million to 1 billion doses globally in 2021.